MTOR and schizophrenia: In conclusion, our study reports that Tanc2 is a regulated mTOR inhibitor with strong neurodevelopmental impacts and that mTOR inhibition could be an effective strategy for treating human individuals with TANC2 mutations suffering from neuropsychiatric disorders, including intellectual disability, ASD, developmental delays, and schizophrenia.